Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Marsh

Showing results (581-590 of 654) with videos related to

Pageof 66
Sort By:
Journal of Medicinal Chemistry|March 4, 1998
Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacyD J Kempf, H L Sham, K C Marsh, et al.
Bioorganic & Medicinal Chemistry|July 31, 1999
Discovery of a series of pyrrolidine-based endothelin receptor antagonists with enhanced ET(A) receptor selectivityS A Boyd, R A Mantei, A S Tasker, et al.
Bioorganic & Medicinal Chemistry Letters|May 18, 2007
Alpha-methylation at benzylic fragment of N-aryl-N'-benzyl ureas provides TRPV1 antagonists with better pharmacokinetic properties and higher efficacy in inflammatory pain modelArthur Gomtsyan, Erol K Bayburt, Ryan Keddy, et al.
Bioorganic & Medicinal Chemistry Letters|May 25, 2005
Synthesis and evaluation of urea-based indazoles as melanin-concentrating hormone receptor 1 antagonists for the treatment of obesityAndrew J Souers, Ju Gao, Dariusz Wodka, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 1996
Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonistT J Opgenorth, A L Adler, S V Calzadilla, et al.
Nature|February 9, 2018
Isomer depletion as experimental evidence of nuclear excitation by electron captureC J Chiara, J J Carroll, M P Carpenter, et al.
Molecular Cancer Therapeutics|September 28, 2016
Development of a Novel Antibody-Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1Lawrence J Thomas, Laura Vitale, Thomas O'Neill, et al.
Cancer Research|May 3, 2008
ABT-263: a potent and orally bioavailable Bcl-2 family inhibitorChristin Tse, Alexander R Shoemaker, Jessica Adickes, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|May 4, 2026
Screening for high-risk drinking and alcohol use disorder: update of the 2023 national clinical practice guidelineEvan Wood, Shirley C Wong, Kim Corace, et al.
Journal of Medicinal Chemistry|October 10, 2008
Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteinsCheol-Min Park, Milan Bruncko, Jessica Adickes, et al.
Pageof 66

Showing results (581-590 of 654) with videos related to

Sort By:
Pageof 66
Journal of Medicinal Chemistry|March 4, 1998
Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacyD J Kempf, H L Sham, K C Marsh, et al.
Bioorganic & Medicinal Chemistry|July 31, 1999
Discovery of a series of pyrrolidine-based endothelin receptor antagonists with enhanced ET(A) receptor selectivityS A Boyd, R A Mantei, A S Tasker, et al.
Bioorganic & Medicinal Chemistry Letters|May 18, 2007
Alpha-methylation at benzylic fragment of N-aryl-N'-benzyl ureas provides TRPV1 antagonists with better pharmacokinetic properties and higher efficacy in inflammatory pain modelArthur Gomtsyan, Erol K Bayburt, Ryan Keddy, et al.
Bioorganic & Medicinal Chemistry Letters|May 25, 2005
Synthesis and evaluation of urea-based indazoles as melanin-concentrating hormone receptor 1 antagonists for the treatment of obesityAndrew J Souers, Ju Gao, Dariusz Wodka, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 1996
Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonistT J Opgenorth, A L Adler, S V Calzadilla, et al.
Nature|February 9, 2018
Isomer depletion as experimental evidence of nuclear excitation by electron captureC J Chiara, J J Carroll, M P Carpenter, et al.
Molecular Cancer Therapeutics|September 28, 2016
Development of a Novel Antibody-Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1Lawrence J Thomas, Laura Vitale, Thomas O'Neill, et al.
Cancer Research|May 3, 2008
ABT-263: a potent and orally bioavailable Bcl-2 family inhibitorChristin Tse, Alexander R Shoemaker, Jessica Adickes, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|May 4, 2026
Screening for high-risk drinking and alcohol use disorder: update of the 2023 national clinical practice guidelineEvan Wood, Shirley C Wong, Kim Corace, et al.
Journal of Medicinal Chemistry|October 10, 2008
Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteinsCheol-Min Park, Milan Bruncko, Jessica Adickes, et al.
Pageof 66